Dr. Shahid Nimjee is an Assistant Professor in the Departments of Neuroscience and Neurological Surgery at the Ohio State University Wexner Medical Center's Comprehensive Stroke Center. His clinical specialties include open and endovascular neurosurgery, and his research focuses on exploiting the properties of RNA biology to better diagnose and treat thromboembolic disease as it pertains to cerebrovascular neurosurgery. He has received the American Heart Association’s New Investigator Award and Duke University’s RNA Award for Research within the Department of Genetics. Dr. Nimjee’s current work centers on development of a novel and reversible drug to treat patients who present with acute ischemic stroke. Earlier in 2019, he published a study in Molecular Therapy that demonstrated promise with this drug: when tested in mice and dogs, the novel drug opened up blocked blood vessels better than traditional clot-removing drugs, and may someday increase the number of patients who can receive acute stroke treatment.
Dr. Nimjee completed his M.D. and Ph.D. at Duke University School of Medicine. He then remained at Duke to complete a residency in neurological surgery and fellowship in endovascular/cerebrovascular neurosurgery.